Oliver A Cornely

Summary

Affiliation: University of Cologne
Country: Germany

Publications

  1. ncbi request reprint Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia
    Oliver A Cornely
    University of Cologne, Cologne, Germany
    N Engl J Med 356:348-59. 2007
  2. ncbi request reprint Randomized controlled monocentric comparison of once daily ceftriaxone with tobramycin and cefotaxime three times daily with tobramycin in neutropenic fever
    O A Cornely
    Department of Internal Medicine I, University Hospital of Cologne, 50924 Cologne, Germany
    Ann Hematol 80:103-8. 2001
  3. ncbi request reprint Is there a role for polyenes in treating invasive mycoses?
    Oliver A Cornely
    First Department of Internal Medicine, Hematology Oncology Infectious Diseases, University Hospital of Cologne, Koln, Germany
    Curr Opin Infect Dis 19:565-70. 2006
  4. ncbi request reprint Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
    Oliver A Cornely
    Klinik I fur Innere Medizin, Klinikum der Universität zu Köln, 50931, Koln, Germany
    Ann Hematol 82:S186-200. 2003
  5. ncbi request reprint Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)
    Oliver A Cornely
    1st Dept of Internal Medicine, University of Cologne, Germany
    Clin Infect Dis 44:1289-97. 2007
  6. ncbi request reprint Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia
    Oliver A Cornely
    Department of Internal Medicine I, Klinikum der Universität zu Köln, Koln, Germany
    Int J Hematol 79:74-8. 2004
  7. pmc Disseminated Neocosmospora vasinfecta infection in a patient with acute nonlymphocytic leukemia
    O A Cornely
    Klinik I fur Innere Medizin, Universitätsklinik Köln, 50924 Köln, Germany
    Emerg Infect Dis 7:149-52. 2001
  8. ncbi request reprint A randomized monocentric trial in febrile neutropenic patients: ceftriaxone and gentamicin vs cefepime and gentamicin
    O A Cornely
    Department of Internal Medicine I, University Hospital of Cologne, Joseph Stelzmann Strasse 9, 50931 Cologne, Germany
    Ann Hematol 81:37-43. 2002
  9. ncbi request reprint [Antifungal prophylaxis in neutropenic patients]
    O A Cornely
    Universitätsklinik I für Innere Medizin, D 50924 Koln, Deutschland
    Wien Med Wochenschr 151:73-9. 2001
  10. ncbi request reprint [Opportunistic infections after treatment with monoclonal antibodies]
    Oliver A Cornely
    Hämatologie, Onkologie, Klinische Infektiologie, Klinikum der Universität Köln, Deutschland
    Wien Med Wochenschr 154:209-17. 2004

Detail Information

Publications89

  1. ncbi request reprint Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia
    Oliver A Cornely
    University of Cologne, Cologne, Germany
    N Engl J Med 356:348-59. 2007
    ..Patients with neutropenia resulting from chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome are at high risk for difficult-to-treat and often fatal invasive fungal infections...
  2. ncbi request reprint Randomized controlled monocentric comparison of once daily ceftriaxone with tobramycin and cefotaxime three times daily with tobramycin in neutropenic fever
    O A Cornely
    Department of Internal Medicine I, University Hospital of Cologne, 50924 Cologne, Germany
    Ann Hematol 80:103-8. 2001
    ..7% and 80%, respectively. No significant difference in toxicity was observed. Once-daily ceftriaxone plus tobramycin was not inferior to cefotaxime t.i.d. plus tobramycin qd in the empirical treatment of neutropenic fever...
  3. ncbi request reprint Is there a role for polyenes in treating invasive mycoses?
    Oliver A Cornely
    First Department of Internal Medicine, Hematology Oncology Infectious Diseases, University Hospital of Cologne, Koln, Germany
    Curr Opin Infect Dis 19:565-70. 2006
    ..In addition to re-examining the landmark clinical trials of the past, the more recent findings are put into perspective. The past year has been particularly rich in clinical trials...
  4. ncbi request reprint Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
    Oliver A Cornely
    Klinik I fur Innere Medizin, Klinikum der Universität zu Köln, 50931, Koln, Germany
    Ann Hematol 82:S186-200. 2003
    ..The objective of this review accumulating information on about 10.000 patients is to assess evidence based criteria primarily regarding the efficacy of antifungal prophylaxis in neutropenic cancer patients...
  5. ncbi request reprint Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)
    Oliver A Cornely
    1st Dept of Internal Medicine, University of Cologne, Germany
    Clin Infect Dis 44:1289-97. 2007
    ..Liposomal amphotericin B achieves maximum plasma levels at a dosage of 10 mg/kg per day, but clinical efficacy data for higher doses are lacking...
  6. ncbi request reprint Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia
    Oliver A Cornely
    Department of Internal Medicine I, Klinikum der Universität zu Köln, Koln, Germany
    Int J Hematol 79:74-8. 2004
    ..A larger phase III trial is warranted to further evaluate the lack of inferiority of the oral monotherapy regimen versus standard intravenous therapy...
  7. pmc Disseminated Neocosmospora vasinfecta infection in a patient with acute nonlymphocytic leukemia
    O A Cornely
    Klinik I fur Innere Medizin, Universitätsklinik Köln, 50924 Köln, Germany
    Emerg Infect Dis 7:149-52. 2001
    ..N. vasinfecta, a plant pathogen, was identified by culture and genetic sequencing. Susceptibility testing revealed in vitro resistance for common antifungals...
  8. ncbi request reprint A randomized monocentric trial in febrile neutropenic patients: ceftriaxone and gentamicin vs cefepime and gentamicin
    O A Cornely
    Department of Internal Medicine I, University Hospital of Cologne, Joseph Stelzmann Strasse 9, 50931 Cologne, Germany
    Ann Hematol 81:37-43. 2002
    ..5% vs 17%), while nausea/vomiting was less (12.1% vs 5%). Once-daily ceftriaxone plus gentamicin was not inferior to cefepime t.i.d. plus gentamicin q.d. in the empirical treatment of neutropenic fever...
  9. ncbi request reprint [Antifungal prophylaxis in neutropenic patients]
    O A Cornely
    Universitätsklinik I für Innere Medizin, D 50924 Koln, Deutschland
    Wien Med Wochenschr 151:73-9. 2001
    ..Nystatin can be used topically whenever topical amphotericin B is not well tolerated. All currently available prophylactic antimycotics bear the risk of either unsatisfactory effectiveness or severe toxicity...
  10. ncbi request reprint [Opportunistic infections after treatment with monoclonal antibodies]
    Oliver A Cornely
    Hämatologie, Onkologie, Klinische Infektiologie, Klinikum der Universität Köln, Deutschland
    Wien Med Wochenschr 154:209-17. 2004
    ..Whether reactivation of herpes simplex and varizella zoster can be influenced prophylactically has not been studied in randomised trials. In case of fever and detection of cytomegalovirus reactivation preemptive therapy should be given...
  11. doi request reprint Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients
    Maria J G T Rüping
    Klinikum der Universität zu Köln, Klinik I fur Innere Medizin, Koln, Germany
    Mycoses 54:230-3. 2011
    ..Future investigations might aim at identifying drug level thresholds that allow for minimum toxicity and optimum efficacy of antifungal prophylaxis...
  12. doi request reprint Intracellular concentrations of micafungin in different cellular compartments of the peripheral blood
    Fedja Farowski
    Universitätsklinikum Köln, Klinik I fur Innere Medizin, Koln, Germany
    Int J Antimicrob Agents 39:228-31. 2012
    ..In vitro data showed that intracellular uptake of micafungin by PBMCs depends on the albumin concentration of the surrounding medium, but only at non-physiological protein concentrations...
  13. doi request reprint Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry
    Jörg J Vehreschild
    Klinik I fur Innere Medizin, Klinikum der Universität zu Köln, Cologne, Germany
    Int J Antimicrob Agents 34:446-50. 2009
    ..Despite antifungal prophylaxis, risk of breakthrough IFD was high in both groups...
  14. pmc Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole
    Jörg J Vehreschild
    Klinikum der Universität zu Köln, Klinik I fur Innere Medizin, Studienzentrum Infektiologie II, Kerpener Strasse 62, Koln, Germany
    Int J Hematol 87:126-31. 2008
    ..Data from this survey demonstrate the difficulty of putting drugs to their approved use in IFI...
  15. ncbi request reprint A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML)
    Jörg J Vehreschild
    Klinikum der Universität zu Köln, Klinik I fur Innere Medizin, Studienzentrum Infektiologie II, 50937 Koln, Germany
    J Infect 55:445-9. 2007
    ..We conducted a trial to analyze the efficacy and safety of voriconazole in the prevention of lung infiltrates during induction chemotherapy for acute myelogenous leukaemia (AML)...
  16. doi request reprint Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question?
    Maria J G T Rüping
    Department I of Internal Medicine, Clinical Trials Unit II for Infectious Diseases, Hospital of the University of Cologne, Koln, Germany
    Leuk Lymphoma 51:20-6. 2010
    ....
  17. pmc Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology
    Oliver A Cornely
    Klinikum der Universität zu Köln, Klinik I für Innere Medizin Zentrum für Klinische Studien BMBF 01KN0706, Koln, Germany
    Haematologica 94:113-22. 2009
    ..Fluconazole 400 mg/d is recommended in allogeneic stem cell recipients until development of graft versus host disease only (Level A I). Aerosolized liposomal amphotericin B is recommended during prolonged neutropenia (Level B II)...
  18. ncbi request reprint Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies
    Oliver A Cornely
    Klinik I fur Innere Medizin, Klinikum der Universität Köln, Cologne, Germany
    Blood 101:3365-72. 2003
    ..The objective of this review of 50 studies accumulating more than 9000 patients is to assess evidence-based criteria with regard to the efficacy of antifungal prophylaxis in neutropenic cancer patients...
  19. doi request reprint Risk factors for breakthrough invasive fungal infection during secondary prophylaxis
    Oliver A Cornely
    Klinik I fur Innere Medizin, Klinikum der Universität Köln, 50924 Köln, Germany
    J Antimicrob Chemother 61:939-46. 2008
    ..This study determines risk factors for recurrent IFI in leukaemia patients...
  20. pmc Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection
    Oliver A Cornely
    Department I for Internal Medicine, University Hospital Cologne, ZKS Köln BMBF 01KN1106, University of Cologne, Cologne, Germany
    Antimicrob Agents Chemother 56:2652-8. 2012
    ..A change in dosing regimen on day 9 did not lead to higher exposures in these "poor absorbers" on day 15. Poor absorption may be enhanced with a high-fat meal, a nutritional supplement, or acidification...
  21. doi request reprint Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients
    Jörg J Vehreschild
    Hospital of the University of Cologne, Department I of Internal Medicine, Clinical Trials Unit II for Infectious Diseases BMBF 01KI0771, Kerpener Strasse 62, 50937 Koln, Germany
    Expert Opin Pharmacother 11:95-113. 2010
    ..There is an ongoing discussion on whether these studies may be applied to transplant patients as well...
  22. pmc Intracellular concentrations of posaconazole in different compartments of peripheral blood
    Fedja Farowski
    Klinikum der Universität zu Köln, Klinik I fur Innere Medizin, Klinisches Studienzentrum 2 für Infektiologie, Fedja Farowski, MSc, 50924 Cologne, Germany
    Antimicrob Agents Chemother 54:2928-31. 2010
    ..Posaconazole reaches high concentrations within human PBMCs and PMNs and is, to a lesser extent, present in RBCs. The high intracellular concentrations might contribute to posaconazole efficacy and distribution...
  23. pmc Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry
    Fedja Farowski
    Klinikum der Universität zu Köln, Klinik I fur Innere Medizin, Klinisches Studienzentrum 2 für Infektiologie, Koln, Germany
    Antimicrob Agents Chemother 54:1815-9. 2010
    ..8%. The method was established as standard practice for the quantitation of intracellular antifungal concentrations and optimizes TDM by applying a rapid single method for 6 antifungals...
  24. doi request reprint Mucormycosis treated with posaconazole: review of 96 case reports
    Joerg J Vehreschild
    1st Department of Internal Medicine, University of Cologne, Cologne, Germany
    Crit Rev Microbiol 39:310-24. 2013
    ..Overall mortality was 24% (lacking data for three patients). In published case reports on posaconazole treatment for mucormycosis, the drug was frequently and successfully used in combination or as second line therapy. ..
  25. doi request reprint Antifungal treatment strategies in high risk patients
    Maria J G T Rüping
    Department I of Internal Medicine, Clinical Trials Unit Infectious Diseases II, Hospital of University of Cologne, Koln, Germany
    Mycoses 51:46-51. 2008
    ..may be switched to fluconazole. Caspofungin or micafungin might be preferred to anidulafungin in the neutropenic patient. L-AmB is a valuable second line treatment option for both groups of patients...
  26. doi request reprint Intracellular concentrations of anidulafungin in different compartments of the peripheral blood
    Fedja Farowski
    Department of Internal Medicine, University of Cologne, Cologne, Germany
    Int J Antimicrob Agents 41:379-82. 2013
    ..In vitro data showed that intracellular uptake of anidulafungin by PBMCs depends on the albumin concentration of the surrounding medium, but only at low, i.e. non-physiological, protein concentrations...
  27. ncbi request reprint Outcomes of nosocomial bloodstream infections in adult neutropenic patients: a prospective cohort and matched case-control study
    Hilmar Wisplinghoff
    Institute for Medical Microbiology, Immunology and Hygiene, and Department of Internal Medicine, University of Cologne, Cologne, Germany
    Infect Control Hosp Epidemiol 24:905-11. 2003
    ..To examine the clinical and epidemiologic features, excess length of stay, extra costs, and mortality attributable to bloodstream infection (BSI) in neutropenic patients with hematologic malignancies...
  28. doi request reprint Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease
    Oliver A Cornely
    Department I of Internal Medicine, Infectious Diseases, University of Cologne, Cologne, Germany
    Mycoses 54:e449-55. 2011
    ..As possible invasive mould disease probably reflects an early-stage of disease, a better outcome might be expected when treatment with liposomal amphotericin B is started preemptively...
  29. ncbi request reprint Anidulafungin--state of affairs from a clinical perspective
    Jörg J Vehreschild
    Klinikum der Universität zu Köln, Klinik I fur Innere Medizin, Klinische Infektiologie, Kerpener Strasse, Koln, Germany
    Mycoses 50:38-43. 2007
    ..Future investigations may elucidate how anidulafungin performs clinically in comparison with the other echinocandins...
  30. doi request reprint Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial
    J Janne Vehreschild
    Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
    Int J Antimicrob Agents 39:130-4. 2012
    ..Moxifloxacin prevented bacteraemia and shortened febrile episodes in patients receiving autologous PBSCT. No significant increase of adverse events in the moxifloxacin arm was observed, possibly due to the rather small sample size...
  31. doi request reprint Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease
    Oliver A Cornely
    Klinik I für Innere Medizin der Universität zu Köln, and Zentrum für Klinische Studien BMBF 01KN0706, Koln, Germany
    Mycoses 54:e838-47. 2011
    ..Further prospective trials are recommended to evaluate comparative outcomes with a primary focus on patients with malignancies and invasive candidiasis...
  32. ncbi request reprint Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice
    Jörg J Vehreschild
    Klinikum der Universität zu Köln, Klinik I fur Innere Medizin, Klinisches Studienzentrum Infektiologie II, Koln, Germany
    Future Microbiol 1:161-70. 2006
    ..More controlled and sufficiently scaled trials are imperative in order to establish micafungin as a reliable and safe option in clinical practice...
  33. ncbi request reprint Patients at high risk of invasive fungal infections: when and how to treat
    Maria J G T Rüping
    Department I of Internal Medicine, Clinical Trials Unit Infectious Diseases II, Hospital of the University of Cologne, Cologne, Germany
    Drugs 68:1941-62. 2008
    ..Early diagnosis of IFIs is imperative to facilitate treatment success. In all patients at risk for IFIs, blood cultures, galactomannan antigen and diagnostic imaging should be rigorously enforced...
  34. ncbi request reprint Posaconazole: a next-generation triazole antifungal
    Fedja Farowski
    Klinikum der Universität zu Köln, Klinik I fur Innere Medizin, Klinisches Studienzentrum Schwerpunkt Infektiologie II, Koln, Germany
    Future Microbiol 2:231-43. 2007
    ....
  35. ncbi request reprint Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman
    Thomas Elter
    1st Department of Internal Medicine, University of Cologne, 50924 Cologne, Germany
    Int J Antimicrob Agents 28:262-5. 2006
    ..Furthermore, for the first time, voriconazole levels in an intracerebral abscess were measured in this patient undergoing voriconazole oral therapy...
  36. ncbi request reprint Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation
    Jörg J Vehreschild
    1st Department of Internal Medicine, University of Cologne, Cologne, Germany
    Mycoses 49:42-7. 2006
    ..Symptoms rapidly resolved under posaconazole 200 mg q.i.d. treatment and the patient was able to undergo allogeneic haematopoietic stem cell transplantation on secondary prophylaxis with posaconazole...
  37. doi request reprint Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab
    Thomas Elter
    Department of Hematology, Oncology and Infectious Diseases, University of Cologne, Cologne, Germany
    Ann Hematol 88:121-32. 2009
    ..In this review article, we provide an overview of common infectious events associated with alemtuzumab therapy in CLL. We also discuss recommendations for effectively monitoring and managing infections in CLL patients...
  38. doi request reprint Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis
    Sebastian M Heimann
    1st Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany
    Mycoses 57:90-7. 2014
    ..3) min. In our hospital, primary antifungal prophylaxis by posaconazole was cost-effective. There was a trend towards cost savings, which was primarily caused by a shorter overall length of stay and the less frequent ICU treatment. ..
  39. doi request reprint Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species
    Oliver A Cornely
    University of Cologne, Cologne, Germany
    Mycoses 57:79-89. 2014
    ..Micafungin, caspofungin and liposomal amphotericin B exhibit favourable treatment response rates that are comparable for patients infected with different Candida spp. ..
  40. doi request reprint [Posaconazole: another triazole antifungal of the new generation?]
    C Muller
    Institut fur Pharmakologie, Uniklinik Köln
    Dtsch Med Wochenschr 133:2345-8. 2008
  41. ncbi request reprint Successful treatment of chronic disseminated candidiasis with caspofungin and itraconazole in a patient with progressive acute leukemia and prolonged neutropenia
    K Hubel
    Klinik I fur Innere Medizin, Klinikum der Universität zu Köln, Joseph Stelzmann Str 9, 50924 Köln, Germany
    Int J Hematol 79:289-92. 2004
    ..This case report describes the successful treatment of CDC during neutropenia using combination antifungal therapy and suggests controlled studies to establish optimal therapeutic strategies...
  42. ncbi request reprint The first echinocandin: caspofungin
    O A Cornely
    Klinik I fur Innere Medizin, Klinikum der Universität Köln, 50924 Köln, Germany
    Mycoses 45:56-60. 2002
    ..Reports of combination therapy or highly effective antifungal treatment (HEAT) in limited patient numbers are promising. New trials of combination therapy are warranted...
  43. ncbi request reprint Long-term outcome and quality of care of patients with Staphylococcus aureus bacteremia
    G Fatkenheuer
    Department of Internal Medicine, University of Cologne, 50924 Cologne, Germany
    Eur J Clin Microbiol Infect Dis 23:157-62. 2004
    ..In order to reduce the considerable mortality associated with SAB and to improve short- and long-term outcome, efforts should be made to increase adherence to recommendations...
  44. ncbi request reprint Improved outcome in central nervous system aspergillosis, using voriconazole treatment
    Stefan Schwartz
    Medizinische Klinik III, Hämatologie, Onkologie und Transfusionsmedizin, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Blood 106:2641-5. 2005
    ..We conclude from this large cohort of patients that voriconazole treatment together with neurosurgical management, whenever feasible, is currently the best approach to treat patients with CNS aspergillosis...
  45. ncbi request reprint Invasive candidiasis and candidemia: from current opinions to future perspectives
    Maria J G T Rueping
    Clinical Trials Unit Infectious Diseases II and Clinical Trials Center Cologne, Kerpener Strasse 62, Koeln, Germany
    Expert Opin Investig Drugs 18:735-48. 2009
    ..Finally, the reader is provided with a brief overview on promising clinical trial designs and antifungals that might shape the treatment of invasive candidiasis in the years to come...
  46. ncbi request reprint Central venous catheter (CVC)-related infections in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
    Gerd Fatkenheuer
    Klinik 1 für Innere Medizin, Klinikum der Universität zu Köln, 50924, Koln, Germany
    Ann Hematol 82:S149-57. 2003
    ..In the future, the rate of catheter-related infections in neutropenic patients may be reduced by the use of catheters coated with antimicrobial agents...
  47. ncbi request reprint Caspofungin for the treatment of less common forms of invasive candidiasis
    Oliver A Cornely
    Klinik I fur Innere Medizin, Klinikum der Universität zu Köln, 50924 Köln, Germany
    J Antimicrob Chemother 60:363-9. 2007
    ..Caspofungin has demonstrated efficacy in invasive candidiasis. However, in a comparative study, most patients (>83%) had candidaemia. Therefore, we performed a study in patients with non-fungaemic invasive candidiasis...
  48. doi request reprint Association of HSV reactivation and pro-inflammatory cytokine levels with the severity of stomatitis after BEAM chemotherapy and autologous SCT
    Maria J G T Rüping
    Uniklinik Köln, Klinik I fur Innere Medizin, Koln, Germany
    Support Care Cancer 19:1211-6. 2011
    ....
  49. doi request reprint Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases
    Oliver A Cornely
    University of Cologne, Clinical Trials Centre Cologne ZKS Köln, BMBF 01KN0706, Germany
    Expert Opin Drug Saf 10:171-83. 2011
    ..To define better the safety profile of micafungin, an analysis of micafungin clinical trial safety data was undertaken...
  50. doi request reprint Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy
    Oliver A Cornely
    Department I for Internal Medicine, ZKS Köln BMBF 01KN1106, University of Cologne, Cologne, Germany
    Eur J Haematol 87:289-301. 2011
    ....
  51. ncbi request reprint HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases
    Carsten Müller
    Department of Pharmacology, University Hospital Cologne, Cologne, Germany
    Mycoses 49:17-22. 2006
    ..Oral bioavailability was especially low in patients with cytostatic therapy and/or bone marrow transplantation. Further studies are needed to establish the therapeutic range of the posaconazole concentrations...
  52. pmc Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation
    V Kohl
    Department of Pharmacology, University of Cologne, Cologne, Germany
    Antimicrob Agents Chemother 54:207-12. 2010
    ..Corresponding adjustments of the starting dose according to the presence of diarrhea and according to age appear to be justified before TDM results are available...
  53. ncbi request reprint Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B
    A Rothe
    Klinik I fur Innere Medizin, Universitat zu Koln, Joseph Stelzmann Str 9, 50931 Cologne, Germany
    Ann Hematol 83:394-7. 2004
    ..The combination therapy described here represents a novel approach to the treatment of Fusarium spp. in the immunocompromised host in whom Fusarium spp. are known to cause disseminated infection with high mortality...
  54. doi request reprint Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany
    O A Cornely
    Klinikum der Universitat, Kerpener Strasse 62, 50924, Koln, Germany
    Curr Med Res Opin 24:1743-53. 2008
    ..To investigate the economic impact of micafungin (MICA) for treatment of invasive candidiasis and candidaemia (systemic Candida infections), a health economic analysis was conducted comparing MICA with liposomal amphotericin B (L-AMB)...
  55. doi request reprint Anidulafungin: advantage for the newcomer?
    Maria J Rüping
    Uniklinik Köln, Klinik I fur Innere Medizin, Klinisches Studienzentrum, Schwerpunkt Infektiologie II, Bachemer Str 86, 50931 Koln, Germany
    Expert Rev Clin Pharmacol 1:207-16. 2008
    ..Significant differences in clinical efficacy or safety favoring anidulafungin over the other echinocandins are yet to be discovered. ..
  56. doi request reprint Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin
    Oliver A Cornely
    Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
    J Clin Oncol 31:2493-9. 2013
    ..Patients with cancer are at increased risk for Clostridium difficile-associated diarrhea (CDAD). Little is known about treatment response...
  57. doi request reprint Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort
    J J Vehreschild
    Klinik I fur Innere Medizin, Klinikum der Universität zu Köln, Koln, Germany
    J Antimicrob Chemother 65:1466-71. 2010
    ..However, the value of prophylaxis has been questioned in centres with a low incidence of invasive fungal diseases (IFDs) and pre-emptive treatment strategies...
  58. doi request reprint Forty-one recent cases of invasive zygomycosis from a global clinical registry
    M J G T Rüping
    1st Department of Internal Medicine, University of Cologne, Cologne, Germany
    J Antimicrob Chemother 65:296-302. 2010
    ..Invasive zygomycosis accounts for a significant proportion of all invasive fungal diseases (IFD), but clinical data on the clinical course and treatment response are limited...
  59. ncbi request reprint Nucleoside-free boosted double PI regimen: significant CD4+ T-cell recovery in patients with poor immunologic response despite virologic suppression
    Clara Lehmann
    1st Department of Internal Medicine, University of Cologne, Germany
    Curr HIV Res 6:555-9. 2008
    ..This treatment strategy may represent an option for patients with poor immunologic responses to antiretroviral therapy despite undetectable viremia...
  60. doi request reprint Current experience in treating invasive zygomycosis with posaconazole
    O A Cornely
    Department I of Internal Medicine, Clinical Trials Unit Infectious Diseases II, University of Cologne Hospital, Cologne, Germany
    Clin Microbiol Infect 15:77-81. 2009
    ..If impaired kidney function is overt or expected on the grounds of, for example, uncontrolled diabetes, primary treatment of zygomycosis with posaconazole is an option...
  61. ncbi request reprint A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation
    O A Cornely
    Department I of Internal Medicine, Hematology, Oncology and Infectious Diseases, University of Cologne, Cologne, Germany
    Bone Marrow Transplant 28:899-901. 2001
    ..This case report describes a novel form of aspergillosis and underlines the need for an aggressive diagnostic approach in severely immunocompromised patients...
  62. doi request reprint Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections
    O A Cornely
    Klinik I fur Innere Medizin, Klinikum der Universität zu Köln, 50924, Cologne, Germany
    Infection 36:296-313. 2008
    ..Knowledge of the pathogenesis of IFIs and the activity, efficacy, and limitations of available treatment options will allow the selection of an appropriate antifungal agent for individual patients...
  63. doi request reprint [The curriculum for rotation physicians within the CHIR-Net]
    N Skoetz
    Regionalzentrum Witten Herdecke Köln des CHIR Net, Koln, Deutschland
    Chirurg 80:466, 468-72. 2009
    ..An important aspect of this network is a qualified advanced training for physicians deployed at the CHIR-Net as part of a job rotation...
  64. ncbi request reprint Acute anterior myocardial infarction as first manifestation of acute myeloid leukemia
    U Jachmann-Jahn
    Medizinische Klinik, Krankenhaus Köln Holweide, Cologne, Germany
    Ann Hematol 80:677-81. 2001
    ..Various conditions can cause a myocardial infarction in leukemias. We discuss the clinical management and the possible reasons for a subtotal thrombotic occlusion of the coronary artery...
  65. ncbi request reprint Choosing a study population for the evaluation of antifungal prophylaxis
    Oliver A Cornely
    Clin Infect Dis 40:1699; author reply 1699-701. 2005
  66. ncbi request reprint Recent developments in the management of invasive fungal infections in patients with hematological malignancies
    Meinolf Karthaus
    Medizinische Klinik II, Evangelisches Johannes Krankenhaus, Schildescher Strasse 99, 33611 Bielefeld, Germany
    Ann Hematol 84:207-16. 2005
    ..This review highlights recent developments in the epidemiology, diagnosis, and treatment in the context of state-of-the-art management of invasive fungal infections in cancer patients...
  67. ncbi request reprint Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia
    Thomas J Walsh
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 351:1391-402. 2004
    ..Caspofungin, a member of the new echinocandin class of compounds, may be an effective alternative that is better tolerated than amphotericin B...
  68. ncbi request reprint Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
    Ernst Rüdiger Kuse
    Klinik für Viszeral und Transplantationschirurgie, Hannover, Germany
    Lancet 369:1519-27. 2007
    ..Invasive candidosis is increasingly prevalent in seriously ill patients. Our aim was to compare micafungin with liposomal amphotericin B for the treatment of adult patients with candidaemia or invasive candidosis...
  69. ncbi request reprint [Current development in the diagnostics and therapy of systemic fungal infections in cancer patients]
    Meinolf Karthaus
    Medizinische Klinik II, Onkologie und Palliativmedizin, Evangelisches Johannes Krankenhaus, Bielefeld, Deutschland
    Wien Med Wochenschr 154:199-208. 2004
    ..Recent developments in the epidemiology, diagnostics and treatment of fungal infections are reviewed and discussed in the context of the current state of art for the management of invasive fungal infections in cancer patients...
  70. ncbi request reprint Itraconazole versus fluconazole for antifungal prophylaxis
    Meinolf Karthaus
    Ann Intern Med 140:579-80; author reply 581-2. 2004
  71. ncbi request reprint Prospective clinical evaluation of a LightCycler-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological s
    Dieter Buchheidt
    III Medizinische Klinik, Universitaetsklinikum Mannheim, Universitaet Heidelberg, Wiesbadenerstrasse 7 11, D 68305 Mannheim, Germany
    Br J Haematol 125:196-202. 2004
    ..In patients at high risk for IA, positive results for Aspergillus by PCR of blood samples are highly suggestive for IA and contribute to the diagnosis...
  72. ncbi request reprint Voriconazole versus liposomal amphotericin B for empirical antifungal therapy
    Andrew J Ullmann
    N Engl J Med 346:1745-7; author reply 1745-7. 2002
  73. ncbi request reprint Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial
    Gernot Reich
    Department of Haematology, Oncology and Tumour Immunology, Charite University Hospital, Campus Buch, Lindenberger Weg, Berlin, Germany
    Br J Haematol 130:265-70. 2005
    ..One patient (0.4%) died from infection. Empirical first-line therapy with MPM as well as with P/T is safe and effective in febrile episodes emerging after ASCT. Higher response rates to primary treatment can be achieved with MPM...
  74. ncbi request reprint Comment on: Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies
    Oliver A Cornely
    J Antimicrob Chemother 57:151-2; author reply 152-4. 2006
  75. doi request reprint [Echinocandins in invasive candidiasis]
    Andreas Glöckner
    Neurologisches Rehabilitationszentrum, Greifswald
    Med Klin (Munich) 103:397-405. 2008
    ....
  76. pmc Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting
    Peter Kaskel
    Outcomes Research, MSD Sharp and Dohme GmbH, Haar, Germany
    Ann Hematol 87:311-9. 2008
    ..The data presented in this scenario show that use of caspofungin in hematology-oncology departments in Germany results in shorter hospital stays and is at least cost-neutral compared to use of L-AmB...
  77. ncbi request reprint Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients
    Georg Maschmeyer
    Department of Internal Medicine, Hematology and Oncology, Klinikum Ernst von Bergmann, Potsdam, Germany
    Drugs 67:1567-601. 2007
    ..Voriconazole prophylaxis may be suitable for prevention of IA as well; however, the results of large clinical trials are still awaited...
  78. ncbi request reprint Zygomycosis--current epidemiological aspects
    Andreas Glöckner
    Neurologisches Rehabilitationszentrum, Greifswald, Germany
    Mycoses 50:50-5. 2007
    ..Currently recruiting multicentre trials on primary prophylaxis of IFI will have to show the preventive effectiveness of antifungals with mould activity and the incidence of zygomycosis under prospectively controlled conditions...
  79. doi request reprint Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death
    Oliver A Cornely
    Clin Infect Dis 46:1626-7; author reply 1627-8. 2008
  80. ncbi request reprint Antifungal prophylaxis for invasive mycoses in high risk patients
    Andrew J Ullmann
    Third Department of Internal Medicine, Klinikum der Johannes Gutenberg Universitat, Mainz, Germany
    Curr Opin Infect Dis 19:571-6. 2006
    ..The purpose of this article is to review recent studies in patient populations at high risk for invasive fungal infections...
  81. ncbi request reprint [Zygomycosis after hematogeneic stem cell transplantation--a current problem?]
    Andreas Glöckner
    Neurologisches Rehabilitationszentrum Greifswald, Karl Liebknecht Ring 26A, 17491 Greifswald
    Med Klin (Munich) 101:724-9. 2006
    ....
  82. ncbi request reprint Second-line treatment in invasive mould infections
    Meinolf Karthaus
    Medizinische Klinik II, Onkologie und Palliativmedizin, Evangelisches Krankenhaus Bielefeld, Med Klinik Hämatologie Onkologie und Palliativmedizin im Johannesstift, Bielefeld, Germany
    Mycoses 49:23-6. 2006
    ..This review highlights the new treatment options for the salvage setting in the context of the state-of-the-art management of IFI in cancer patients...
  83. ncbi request reprint Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections
    Issam I Raad
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Infect Dis 42:1726-34. 2006
    ..Antifungal therapy is often required for long periods. Safety data from the clinical development program of the triazole antifungal agent, posaconazole, were analyzed...
  84. ncbi request reprint Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany
    Jeroen P Jansen
    Mapi Values, Houten, The Netherlands
    Value Health 9:12-23. 2006
    ..To assess the costs and cost-effectiveness of voriconazole in comparison to conventional amphotericin B (CAB) for the treatment of invasive aspergillosis in Germany...
  85. ncbi request reprint Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt
    Elias J Anaissie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Clin Infect Dis 43:1031-9. 2006
  86. ncbi request reprint [Vaccination of the immunocompromised host]
    Andrew J Ullmann
    III Medizinische Klinik und Poliklinik, Klinikum der Johannes Gutenberg Universitat, Mainz, Deutschland
    Wien Med Wochenschr 154:218-25. 2004
    ..Immunocompromised hosts with cancer will benefit from consistent immunization practices. Further clinical trials are urgently warranted...
  87. ncbi request reprint Diagnosis and treatment of documented infections in neutropenic patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
    Dieter Buchheidt
    III Medizinische Klinik, Universitatsklinikum Mannheim, Ruprecht Karls Universitat Heidelberg, Wiesbadener Strasse 7 11, 68305, Mannheim, Germany
    Ann Hematol 82:S127-32. 2003
    ..The response rate is significantly lower in documented infections than in fever of unknown origin (FUO). Evidence-based recommendations for diagnosis and treatment procedures are presented, reflecting study results and expert opinions...
  88. ncbi request reprint Peripheral Teflon catheters: factors determining incidence of phlebitis and duration of cannulation
    Oliver A Cornely
    Department I of Internal Medicine, Cologne University Hospital, Germany
    Infect Control Hosp Epidemiol 23:249-53. 2002
    ..Risk factors for catheter-related phlebitis were assessed at a single tertiary-care institution where no routine change policy for peripheral intravenous catheters is in place...
  89. ncbi request reprint Treatment options in candidaemia
    Meinolf Karthaus
    Department Hematology Oncology and Palliative Care, Ev Krankenhaus Bielefeld, Med Klinik im Johannesstift, Schildescher Strasse, Bielefeld
    Mycoses 50:44-9. 2007
    ..With the advent of new antifungals the efficacy and safety of antifungal treatment have been improved substantially. This review summarises the new treatment options in candidaemia...